147 related articles for article (PubMed ID: 35852051)
1. Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real-world database study.
Cranmer LD; Hess LM; Sugihara T; Muntz HG
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1681. PubMed ID: 35852051
[TBL] [Abstract][Full Text] [Related]
2. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).
Cranmer LD; Lu Y; Heise RS; Ballman KV; Loggers ET; Pollack SM; Wagner MJ; Reinke DK; Schöffski P; Tap WD
Clin Cancer Res; 2023 Mar; 29(6):1068-1076. PubMed ID: 36622694
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
[TBL] [Abstract][Full Text] [Related]
8. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Jones RL; Wagner AJ; Kawai A; Tamura K; Shahir A; Van Tine BA; Martín-Broto J; Peterson PM; Wright J; Tap WD
Clin Cancer Res; 2021 Jul; 27(14):3861-3866. PubMed ID: 33632930
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy.
Ghiami H; Omidkhoda N; Seddigh-Shamsi M; Rahimi H; Arasteh O
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; ():. PubMed ID: 38095650
[TBL] [Abstract][Full Text] [Related]
10. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
11. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
13. Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin.
Vitfell-Rasmussen J; Krarup-Hansen A; Vaage-Nilsen M; Kümler T; Zerahn B
Acta Oncol; 2022 Jul; 61(7):801-808. PubMed ID: 35695121
[TBL] [Abstract][Full Text] [Related]
14. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
15. Continuous venous infusion of doxorubicin in advanced sarcomas.
Samuels BL; Vogelzang NJ; Ruane M; Simon MA
Cancer Treat Rep; 1987 Oct; 71(10):971-2. PubMed ID: 3652058
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Huh WW; Jaffe N; Durand JB; Munsell MF; Herzog CE
Pediatr Hematol Oncol; 2010 Oct; 27(7):546-57. PubMed ID: 20795769
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Jones RL; Herzog TJ; Patel SR; von Mehren M; Schuetze SM; Van Tine BA; Coleman RL; Knoblauch R; Triantos S; Hu P; Shalaby W; McGowan T; Monk BJ; Demetri GD
Cancer Med; 2021 Jun; 10(11):3565-3574. PubMed ID: 33960681
[TBL] [Abstract][Full Text] [Related]
19. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
